🔗 Share this article

Elected officials have raised concerns that the United Kingdom's negotiated accords with Donald Trump are "lacking a solid foundation." This stems from revelations that a recently announced deal on medicines, which promises zero tariffs in exchange for the NHS facing higher prices, lacks any underlying contract beyond limited headline terms published in government press releases.

Lacking Legal Footing

The arrangement concerning medicines, hailed as a "landmark" achievement, is still an "broad understanding" without a signed legal text. It has been highlighted that the public statements from the UK and US governments frame the deal in markedly contrasting terms. The British version focuses on securing "duty-free access" as a singular success, while the American announcement highlights the expectation for the NHS to pay significantly more for new medications.

"We face a genuine possibility that the UK government has promised concessions to increase medicine costs in return for only a pledge from President Trump," commented David Henig, a trade expert. "We know he has a tendency for not keeping promises."

Broader Instability and a Paused Tech Deal

Anxieties have been intensified by Washington's move to suspend the high-value digital accord, which was previously described as "a generational step-change" in the bilateral relationship. The US cited a failure to advance from the UK on addressing wider trade issues as the reason for the pause.

Furthermore, concessions secured for British farmers as part of an initial accord have still not been formally signed off by the US, despite a imminent January deadline. "Our understanding is that the US has not finalized the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have voiced worries that the government's agreements with the US are flimsy and unreliable. One minister reportedly said the series of agreements as "built on sand," while another framed the situation as the "current reality" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, a senior MP on the health committee, remarked: "The only thing more surprising than Trump's temper tantrums is the UK government's credulous faith that his administration is a trustworthy negotiator. The NHS is not a bargaining chip."

Official Reassurances and Concrete Outcomes

Government figures have sought to reduce the possibility of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been advocating for the agreement, seeking certainty on imports and pricing, making it less abstract than the paused tech deal.

Officials acknowledge that unpredictability is a feature of dealing with the Trump administration. However, they maintain that the UK has secured concrete outcomes for businesses, such as lower steel tariffs compared to other nations. "The fact we have 25% steel tariffs, which is lower than the rate for the rest of the world, is a solid gain," one official said.

Yet, problems have arisen in enacting the initial US-UK accord. Promised access for British beef have failed to be approved, and the assurance to "reduce steel tariffs to zero" has is still pending, with tariffs staying at 25%.

As negotiations continue, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.